1042 related articles for article (PubMed ID: 8654629)
21. Effects of long-term low-dose mifepristone on reproductive function in women.
Croxatto HB; Kovács L; Massai R; Resch BA; Fuentealba B; Salvatierra AM; Croxatto HD; Zalányi S; Viski S; Krenács L
Hum Reprod; 1998 Apr; 13(4):793-8. PubMed ID: 9619526
[TBL] [Abstract][Full Text] [Related]
22. Effects of intranasal administration of norethisterone on folliculogenesis, cervical mucus, vaginal cytology, endometrial morphology and reproductive-endocrine profile in women.
Kumar TC; Shah RS; Chitlange SM; Hazari KT; Gopalkrishnan K; Vadigoppula AD; Vernekar VJ; Borkar DM; Puri CP
Contraception; 1991 Sep; 44(3):245-67. PubMed ID: 1764942
[TBL] [Abstract][Full Text] [Related]
23. Ovarian function during use of a levonorgestrel-releasing IUD.
Barbosa I; Bakos O; Olsson SE; Odlind V; Johansson ED
Contraception; 1990 Jul; 42(1):51-66. PubMed ID: 2117516
[TBL] [Abstract][Full Text] [Related]
24. Ultrasonographic and endocrine evaluation of ovarian function among Norplant implants users with regular menses.
Alvarez F; Brache V; Faundes A; Tejada AS; Thevenin F
Contraception; 1996 Nov; 54(5):275-9. PubMed ID: 8934060
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
Lemay A; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
[TBL] [Abstract][Full Text] [Related]
26. The use of nomegestrol acetate subdermal contraceptive implant, uniplant, during lactation.
Abdel-Aleem H; Abol-Oyoun el-S M; Shaaban MM; el-Saeed M; Shoukry M; Makhlouf A; Salem HT
Contraception; 1996 Nov; 54(5):281-6. PubMed ID: 8934061
[TBL] [Abstract][Full Text] [Related]
27. One year contraception with a single subdermal implant containing nomegestrol acetate (Uniplant).
Coutinho EM
Contraception; 1993 Jan; 47(1):97-105. PubMed ID: 8436005
[TBL] [Abstract][Full Text] [Related]
28. Effect of nomegestrol acetate on spinability, ferning and mesh dimension of midcycle cervical mucus.
Chretien FC; Dubois R
Contraception; 1991 Jan; 43(1):55-65. PubMed ID: 2004529
[TBL] [Abstract][Full Text] [Related]
29. Correlation between the serum norethindrone (NET) levels attained after insertion of a silastic implant releasing norethindrone acetate and the endogenous hormones particularly progesterone.
Laumas V; Jain AK; Jha P; Rahman SA; Kumar D; Malik BK; Sarkar NN; Takkar D; Hingorani V; Laumas KR
Contraception; 1981 Feb; 23(2):211-25. PubMed ID: 6786828
[TBL] [Abstract][Full Text] [Related]
30. Endometrial histology and circulating levels of medroxyprogesterone acetate (MPA), estradiol, FSH and LH in women with MPA induced amenorrhoea compared with women with secondary amenorrhoea.
Jeppsson S; Johansson ED; Ljungberg O; Sjöberg NO
Acta Obstet Gynecol Scand; 1977; 56(1):43-8. PubMed ID: 842303
[TBL] [Abstract][Full Text] [Related]
31. Interruption of endometrial maturation without hormonal changes by an antiprogesterone during the first half of luteal phase of the menstrual cycle: a contraceptive potential.
Greene KE; Kettel LM; Yen SS
Fertil Steril; 1992 Aug; 58(2):338-43. PubMed ID: 1633899
[TBL] [Abstract][Full Text] [Related]
32. Timing of onset of contraceptive effectiveness in Norplant implant users. Part I. Changes in cervical mucus.
Dunson TR; Blumenthal PD; Alvarez F; Brache V; Cochon L; Dalberth B; Glover L; Remsburg R; Vu K; Katz D
Fertil Steril; 1998 Feb; 69(2):258-66. PubMed ID: 9496339
[TBL] [Abstract][Full Text] [Related]
33. Phase I comparative clinical trial with subdermal implants--bioabsorbable levonorgestrel or norethisterone pellet fused with cholesterol.
Joshi UM; Joshi JV; Donde UM; Sankoli GM; Virkar KD; Saxena BN
Contraception; 1985 Jan; 31(1):71-82. PubMed ID: 3921309
[TBL] [Abstract][Full Text] [Related]
34. Shorter pill-free interval in combined oral contraceptives decreases follicular development.
Spona J; Elstein M; Feichtinger W; Sullivan H; Lüdicke F; Müller U; Düsterberg B
Contraception; 1996 Aug; 54(2):71-7. PubMed ID: 8842582
[TBL] [Abstract][Full Text] [Related]
35. Ovarian activity during regular oral contraceptive use.
Crosignani PG; Testa G; Vegetti W; Parazzini F
Contraception; 1996 Nov; 54(5):271-3. PubMed ID: 8934059
[TBL] [Abstract][Full Text] [Related]
36. Studies on sustained contraceptive effects with subcutaneous polydimethylsiloxane implants. 2. Maintenance of ovarian function in patients with megestrol acetate implants.
Benagiano G; Ermini M; Carenza L; Donini P
Acta Endocrinol (Copenh); 1973 Jun; 73(2):347-59. PubMed ID: 4740834
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions.
Heikinheimo O; Gordon K; Williams RF; Hodgen GD
Contraception; 1996 Jan; 53(1):55-64. PubMed ID: 8631191
[TBL] [Abstract][Full Text] [Related]
38. The effect of levonorgestrel administered in large doses at different stages of the cycle on ovarian function and endometrial morphology.
Landgren BM; Johannisson E; Aedo AR; Kumar A; Shi YE
Contraception; 1989 Mar; 39(3):275-89. PubMed ID: 2496951
[TBL] [Abstract][Full Text] [Related]
39. Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring.
Weisberg E; Fraser IS; Lacarra M; Mishell DR; Alvarez F; Brache V; Nash HA
Contraception; 1999 May; 59(5):311-8. PubMed ID: 10494485
[TBL] [Abstract][Full Text] [Related]
40. Contraception with an LHRH agonist: effect on gonadotrophin and steroid secretion patterns.
Kuhl H; Jung C; Taubert HD
Clin Endocrinol (Oxf); 1984 Aug; 21(2):179-88. PubMed ID: 6432376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
